Alper Fatih Ardic¹, Nurittin Ardic^2,*

BIOCELL, Vol.50, No.10, 2026, DOI:10.32604/biocell.2026.082812 - 22 September 2026

Abstract Neutrophil extracellular traps (NETs) are increasingly recognized as significant contributors to neurovascular damage following ischemic brain injuries. This review examines how NETs link intravascular thrombosis to downstream neuroinflammation via a pathway-centric framework. We synthesize recent preclinical and clinical evidence showing that NET-derived histones, extracellular DNA, and granular enzymes activate convergent inflammatory pathways, including the high mobility group box 1–Toll-like receptor 4 axis, nuclear factor kappa B, Janus kinase 2/signal transducer and transcription activator 3, NOD-like receptor pyrin domain-containing 3 inflammasome, and cyclic GMP–AMP synthase–interferon gene signaling. These mechanisms contribute to disruption of the blood-brain barrier, More >

Bharath Kumar Velmurugan¹, Shu Hui Lin^2,3,4, Chih-Yang Huang^5,6,7,8,9,10, Ming-Ju Hsieh^9,11,12,*, Rathinasamy Baskaran^10,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.083159 - 13 August 2026

Abstract Mitochondria are central regulators of cellular metabolism and survival and play a pivotal role in cancer development and progression through the production of reactive oxygen species (ROS), control of calcium homeostasis, regulation of autophagy, and modulation of cell death pathways. Mitochondria-derived ROS (mtROS) act as signaling mediators that influence tumor initiation, proliferation, metabolic reprogramming, metastasis, and therapeutic resistance by altering redox homeostasis, damaging mitochondrial DNA, and reshaping the tumor microenvironment. In addition to meeting the bioenergetic and biosynthetic requirements of rapidly proliferating cancer cells, mitochondrial metabolism modulates immune responses and supports cancer cell adaptation to More >

Emmanuel Naveen Raj^1,#, Chia-Jung Li^1,2,3,4,5,#, Shih-Hsuan Cheng¹, Su-Boon Yong^6,7, Zhi-Hong Wen^3,8, An-Jen Chiang^1,9,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.079551 - 13 August 2026

Abstract Objectives: Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) necessitate the discovery of novel biomarkers for prognostic and therapeutic advancement. This study aims to evaluate the clinical significance of ubiquitin-conjugating enzyme E2C (UBE2C) and its association with the tumor microenvironment (TME) in CESC. Methods: We meticulously sourced CESC data from renowned repositories such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and Gene Expression Omnibus (GEO), leveraging cutting-edge techniques including single-cell RNA sequencing (scRNA-seq), spatial transcriptomics, and pharmacogenomics. Through multifaceted data analysis, we endeavored to unravel the intricate role and potential value of UBE2C in… More > Graphic Abstract

Lisa J. Frey^1,*, Nina Lache¹, Nikita D. Fischer¹, Niklas Rölz¹, Lisa Frey¹, Maximilian Haack¹, Gregor Duwe¹, Stefan Porubsky², Axel Haferkamp¹, Daniel-C. Wagner^2,3, Maximilian P. Brandt¹

Oncology Research, Vol.34, No.8, 2026, DOI:10.32604/or.2026.078954 - 16 July 2026

Abstract Objectives: Squamous cell carcinoma (SCC) of the bladder is an aggressive histologic subtype with distinct clinical behavior and limited treatment options after platinum-based chemotherapy. This study aimed to evaluate potential therapeutic targets in bladder SCC. Methods: A retrospective cohort of 790 patients who underwent radical cystectomy for bladder cancer between 2011 and 2021 was screened to identify cases with histologically confirmed SCC. All SCC cases in the pathology department from 2003 to 2011 were also reviewed. Clinical and pathological data from 54 patients were analyzed. A tissue microarray (TMA) was constructed, and immunohistochemical (IHC) analyses… More >

Jian-Lei Kang^1,2, Yu-Jie Xu³, Qi-Tai Zhao⁴, Bing Zhang⁵, Xin Xu^2,*, Bo Yang^1,*

Oncology Research, Vol.34, No.7, 2026, DOI:10.32604/or.2026.079221 - 16 June 2026

Abstract Background: Glioma is among the most malignant brain tumors, and its heterogeneity contributes significantly to treatment failure. Comprehensive profiling of cellular and molecular heterogeneity across different glioma stages and recurrence states is crucial for understanding therapeutic resistance and identifying novel targets. Accordingly, this study sought to systematically characterize the cellular and molecular heterogeneity of glioma across different stages and recurrence states using single-cell RNA sequencing, and to identify prognostic subtypes and potential therapeutic targets. Methods: We integrated public single-cell RNA sequencing data from glioma specimens, including lower-grade glioma (LGG), glioblastoma (GBM), and paired primary and recurrent… More >

Wen-Hsin Hsu^1,2,#, Kai-Fu Chang^3,4,#, Chih-Hsuan Chang^3,4, Hui-Ru Lin^5,6, Chi-Jen Wu^5,7, Ching-Chung Ko^8,9,10, Cheng-Chun Wu¹¹, Yu-Cheng Ho¹¹, Chih-Chun Lin¹², Chien-Han Yuan^3,5,13,14, Sachin Kumar^15,16, Dahlak Daniel Solomon¹⁵, Fitria Sari Wulandari¹⁵, Juan Lorell Ngadio¹⁷, Do Thi Minh Xuan¹⁸, Chung-Bao Hsieh¹⁹, Chung-Chieh Chiao²⁰, Ngoc Uyen Nhi Nguyen^21,22, Chih-Yang Wang^15,20, Yung-Kuo Lee^3,4,5,*

Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.070445 - 21 May 2026

Abstract Background: Glycosylation and inflammation are pivotal in tumor progression, yet the specific glycosyltransferases bridging these processes remain poorly defined. This study investigated Exostosin-1 (EXT1), a key enzyme in heparan sulfate (HS) biosynthesis, as a mechanistic bridge connecting inflammation, stromal remodeling, and immune evasion-driven cancers. Methods: We used a multi-omics approach including Least Absolute Shrinkage and Selection Operator (LASSO) Cox regression on The Cancer Genome Atlas (TCGA) pan-cancer cohorts, transcriptomics, survival, single-cell RNA sequencing (scRNA-seq), DNA methylation profiling, pathway enrichment analysis (MetaCore), molecular docking, and immunohistochemistry (IHC) on pancreatic adenocarcinoma (PAAD) and lung adenocarcinoma (LUAD) tissue microarrays. Results:… More >

Ya-Ling Yang^1,#, Ying-Hsien Huang^2,#, Hung-Yu Lin^3,4,*

Oncology Research, Vol.34, No.5, 2026, DOI:10.32604/or.2026.075284 - 22 April 2026

Abstract Background: Hepatocellular carcinoma (HCC) presents with poor treatment outcomes, creating an urgent need for novel biomarkers to improve diagnosis, prognosis, and precision medicine. While the MYB family of oncogenes is implicated in cancer, the role and regulatory mechanisms of its member, particularly MYB proto-oncogene like 2 (MYBL2), remain underexplored in HCC. Therefore, this study aimed to systematically validate the clinical significance of MYBL2, elucidate its functional role in tumor progression and drug sensitivity, and identify its upstream regulatory mechanisms using an integrative machine learning and experimental framework. Methods: We applied an integrative pipeline combining LASSO-based… More > Graphic Abstract

Masanobu Tsubaki^*, Taira Matsuo, Rie Komori

Oncology Research, Vol.34, No.5, 2026, DOI:10.32604/or.2025.075217 - 22 April 2026

Abstract Chronic myeloid leukemia (CML) is a hematopoietic malignancy originating from hematopoietic stem cells. It is characterized by the Philadelphia chromosome, which arises from a reciprocal translocation between chromosomes 9 and 22. The breakpoint cluster region::Abelson murine leukemia 1 (BCR::ABL1) fusion protein produced from this chromosome is the main factor responsible for disease onset. Tyrosine kinase inhibitors (TKIs) have led to significant advances in CML treatment and contributed to improved patient survival rates. Nonetheless, a substantial number of patients develop resistance to TKIs, which remains a major challenge in CML therapy. Currently, two mechanisms are considered More >

Jiaxi Li^#, Deepak Iyer^#, Siming Sui, Zheng Huang, Ryan Wai-Yan Sin, Abraham Tak-Ka Man, Wai-Lun Law, Chi-Chung Foo^*, Lui Ng^*

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2026.074981 - 23 March 2026

Abstract Objectives: Piwi-associated RNAs are small non-coding RNAs implicated in cancer, yet few have been characterized in colorectal cancer (CRC). This study aimed to identify a CRC-related piRNA and investigate its clinical relevance, biological function, and biomarker potential. Methods: Candidates were identified by reanalysis of small-RNA sequencing. piR-37524 was quantified by quantitative real-time polymerase chain reaction (qRT-PCR) in colorectal cancer tissues, matched adjacent non-tumor tissues, colorectal adenomas, liver metastases, and serum samples from patients and healthy controls. Clinicopathological correlations and diagnostic performance were evaluated. Functional assays included 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) proliferation, colony formation, and wound-healing migration… More >

Zheng Qin^1,2,#, Yueyao Zhang^3,#, Dongze Liu^4,#, Xiaokang Zheng⁵, Kaibin Wang^1,2, Xiao Zhu^1,2, Yuanhao Zhang^1,2, Kexin Xu^1,2, Changying Li^1,2, Lijuan Kang^1,2, Lili Wang^1,2, Haitao Wang^1,2,*

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2025.073455 - 23 March 2026

Abstract Objective: Prostate cancer is the second most common fatal cancer in men. Identifying new biological therapeutic targets is crucial to effectively improve the prognosis of prostate cancer patients. Ovarian tumor family deubiquitinase 4 (OTUD4) is a member of the ovarian tumor-associated protease domain (OTUDs) family. Although previous studies have shown that the expression and function of OTUD4 vary across different tumors, its role in prostate cancer remains unknown. The aim of this study is to explore new therapeutic targets and diagnostic markers for prostate cancer and investigate their mechanisms of action. Methods: Cell culture, Cell… More >